• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.

作者信息

William Sandborn, Geert D'Haens, Doug Wolf, Stephen Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Hua, Hwan Lee Ji, Lorna Charles, Keith Usiskin, Silvio Danese, Brian Feagan

机构信息

University of California San Diego, San Diego, United States.

Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, Netherlands.

出版信息

Am J Gastroenterol. 2020 Dec 1;115(Suppl 1):S6-S7. doi: 10.14309/01.ajg.0000722896.32651.d6.

DOI:10.14309/01.ajg.0000722896.32651.d6
PMID:33566499
Abstract
摘要

相似文献

1
P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.P025：3期真实北方研究中中度至重度溃疡性结肠炎患者诱导期奥扎莫德的疗效、安全性及组织学表现
Am J Gastroenterol. 2020 Dec 1;115(Suppl 1):S6-S7. doi: 10.14309/01.ajg.0000722896.32651.d6.
2
P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.P030：在3期“真正的北方”研究中，中度至重度溃疡性结肠炎患者维持期使用奥扎莫德的疗效、安全性及组织学情况。
Am J Gastroenterol. 2020 Dec 1;115(Suppl 1):S8. doi: 10.14309/01.ajg.0000722916.98351.89.
3
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.奥扎莫德诱导和维持治疗溃疡性结肠炎。
N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.
4
Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.中度至重度溃疡性结肠炎治疗的系统评价和网状Meta分析
Int J Clin Pharm. 2018 Dec;40(6):1411-1419. doi: 10.1007/s11096-018-0743-4. Epub 2018 Nov 26.
5
Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis.急性重度溃疡性结肠炎中环孢素诱导治疗后奥扎莫德维持治疗
ACG Case Rep J. 2022 Jul 21;9(7):e00832. doi: 10.14309/crj.0000000000000832. eCollection 2022 Jul.
6
P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension.P031：奥扎莫德治疗中重度溃疡性结肠炎患者：2期TOUCHSTONE研究4年开放标签扩展研究的长期安全性和疗效
Am J Gastroenterol. 2020 Dec 1;115(Suppl 1):S8. doi: 10.14309/01.ajg.0000722920.48091.e7.
7
P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study.P012：在3期“真正的北方”研究中，奥扎尼莫德降低了溃疡性结肠炎患者的粪便钙卫蛋白水平。
Am J Gastroenterol. 2020 Dec 1;115(Suppl 1):S3. doi: 10.14309/01.ajg.0000722844.18503.37.
8
Analyses From the Phase 3 True North Study of Ozanimod in Ulcerative Colitis Patients.溃疡性结肠炎患者奥扎莫德3期真实世界研究分析
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):5-6.
9
Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North.奥扎莫德诱导中重度活动性溃疡性结肠炎患者出现症状缓解和病情缓解的速度：来自True North诱导期的结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):2-3.
10
Post Hoc Analyses of the True North Study Evaluating Ozanimod in Patients with Ulcerative Colitis.评估奥扎莫德治疗溃疡性结肠炎患者的“北极星研究”的事后分析
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):3-4.

引用本文的文献

1
Advanced combination therapy: is it the best way to break the therapeutic ceiling?先进的联合疗法：它是突破治疗上限的最佳方法吗？
Therap Adv Gastroenterol. 2024 Oct 24;17:17562848241272995. doi: 10.1177/17562848241272995. eCollection 2024.
2
IBD therapeutics: what is in the pipeline?炎症性肠病治疗方法：正在研发的有哪些？
Frontline Gastroenterol. 2022 Jun 15;13(e1):e35-e43. doi: 10.1136/flgastro-2022-102130. eCollection 2022.
3
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
炎症性肠病中抗肿瘤坏死因子治疗无应答及应答丧失的管理
Front Med (Lausanne). 2022 Jun 15;9:897936. doi: 10.3389/fmed.2022.897936. eCollection 2022.